Posttransplant lymphoproliferative disease: Pathogenesis, monitoring, and therapy

Research output: Contribution to journalReview article

Abstract

The spectrum of transplant-related lymphoproliferative diseases is expanding to include a variety of neoplasias that typically occur late after transplant including Epstein-Barr virus (EBV)-negative B- and T-cell lymphomas, EBV-positive T-cell lymphoma, myeloma, plasmacytoma, and Hodgkin's disease. New approaches to diagnosis and monitoring based on quantitative polymerase chain reaction for EBV DNA are being explored. What exactly is being measured (the source and character of the viral DNA) remains to be determined, as does the compartment that should be assayed (whole blood, serum plasma, or lymphocytes). These questions not withstanding, there is an emerging consensus that these technologies will facilitate rapid diagnosis and therapeutic monitoring in the future. A myriad of therapeutic interventions are or will become available. Rituximab, alone or in addition to other therapies, promises a profound change in the landscape with regard to the treatment and perhaps the prevention of posttransplant lymphoproliferative disease. New approaches to adoptive cellular immunotherapy, including use of EBV-specific products from unrelated donors, nonspecifically activated autologous products, and genetically engineered T cells, are all being explored.

Original languageEnglish (US)
Pages (from-to)359-363
Number of pages5
JournalCurrent oncology reports
Volume5
Issue number5
DOIs
StatePublished - Sep 2003

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Posttransplant lymphoproliferative disease: Pathogenesis, monitoring, and therapy'. Together they form a unique fingerprint.

  • Cite this